摩根士丹利：下调中国中药评级至“减持”

Group 1 - Morgan Stanley issued a report stating that China Traditional Chinese Medicine has released a profit warning, with performance significantly below market expectations [1] - The rating for China Traditional Chinese Medicine has been downgraded from "In Line with Market" to "Underweight," and the target price has been reduced from HKD 2.6 to HKD 1.7 [1] - Morgan Stanley has cut its 2024 earnings forecast by 80% and reduced the earnings projections for 2025 to 2030 by 22% to 34% due to factors such as price reductions, increased market competition, and rising raw material costs impacting sales and profits [1]